Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Maastricht – page 24

326 clinical trials in Maastricht, The Netherlands across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Maastricht at a glance
326
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

326 trials in Maastricht

Open in trial search

Non-small cell lung cancer

Not recruiting

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Hypertension

Not recruiting

Study on the Effectiveness of Ethanol in Treating Hypertension in Patients with Uncontrolled High Blood Pressure

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Ablative Solutions Inc.

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Celgene Corp.

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan for Patients with Advanced Kidney Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Hypertrophic cardiomyopathy

Not recruiting

Long-term Safety Study of Mavacamten for Adults with Hypertrophic Cardiomyopathy from Previous Trials

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bay 3018250
  • Sponsor:Bayer AG

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Maastricht

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer, and melanoma treatments. Studies include novel therapy combinations and personalized treatment approaches.

  • Advanced treatment protocols for metastatic conditions
  • Immunotherapy interventions
  • Diagnostic imaging improvements

Particular emphasis on targeted therapies and treatment optimization for various cancer types.

02 Chronic Disease Management

Research focusing on chronic kidney disease, fibromyalgia, and inflammatory bowel conditions. Studies evaluate new therapeutic approaches and treatment combinations.

  • Novel drug combinations
  • Disease progression monitoring
  • Quality of life improvements

Emphasis on developing effective long-term management strategies for chronic conditions.

03 Cardiovascular Studies

Investigations into peripheral arterial disease and cardiomyopathy treatments. Research includes innovative therapeutic approaches and preventive strategies.

  • Cardiovascular risk reduction
  • Treatment optimization
  • Disease prevention protocols

Focus on improving patient outcomes through targeted interventions and preventive measures.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.